Abstract
The author review recently reported positive outcomes of studies in patients with acute venous thromboembolic disease (RE-COVER) and in patients with atrial fibrillation who are at risk of stroke (RE-LY) have provided further evidence of dabigatran efficacy and safety. Key words: venous thromboembolism – atrial fibrilation – dabigatran